ArticleNeuroImage. Clinical2018
FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease.
Article in NeuroImage. Clinical, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04551040 (Assessing Target Engagement of Terazosin in Healthy Adults), which is not on this map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessing Target Engagement of Terazosin in Healthy Adults
Who cites it
62 citing papers in PubMed.
- Alterations in relative perfusion and synaptic patterns in Parkinson's disease using dynamic SV2A PET.medRxiv : the preprint server for health sciences · 2026Article
- A review of FDG-PET biomarker analysis methods in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Identifing two distinct cortical progression subtypes of Parkinson's disease through multimodal neuroimaging.European journal of nuclear medicine and molecular imaging · 2026Article
- Lactate dynamics in Parkinson's disease: striatal circuit vulnerability, biomarker potential, and therapeutic windows.Molecular medicine (Cambridge, Mass.) · 2026Review
- Preparing for Parkinson's disease prevention trials: Current progress and future directions.Journal of Parkinson's disease · 2026Review
- Novel insights into relationships between metabolic covariance patterns of FDG-PET data and clinical status in Parkinson's disease using partial least squares correlation analysis.Journal of Parkinson's disease · 2026Article
- Elevated cerebral oxygen extraction fraction in Parkinson's disease correlates with motor impairment severity.Scientific reports · 2026Article
- Integrated PET/MRI for the evaluation of gray matter atrophy and metabolic changes in idiopathic Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Age-related changes to brain energetics revealed by PET/MRI imaging.NeuroImage. Clinical · 2026Article
- The role of exercise intensity in motor and non-motor symptoms of Parkinson's disease: mechanisms, clinical evidence, and personalized exercise prescription parameters.Frontiers in aging neuroscience · 2026Review
- Pathway Anchored Multimodal Clustering Reveals Circuit Level Signatures in Parkinsons Disease.bioRxiv : the preprint server for biology · 2025Article
- Assessment of [Biomolecules · 2025Article
- Multimodal metabolic and functional network signatures for diagnosis of parkinson's disease: a PET/MR study.Scientific reports · 2025Article
- Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.Movement disorders : official journal of the Movement Disorder Society · 2025Review
- Improving the Quality of Brain PET Images Using MR-Guided PET Reconstruction Technique With Integrated PET/MR.Human brain mapping · 2025Article
- Imaging advances to detect non-motor prodromal markers of Parkinson's disease and explore therapeutic translation opportunities.NPJ Parkinson's disease · 2025Review
- Neural Metabolic Networks: Key Elements of Healthy Brain Function.Journal of neurochemistry · 2025Review
- Microglial Activation Visualized by [European journal of neurology · 2025Article
- Exploring glycolytic enzymes in disease: potential biomarkers and therapeutic targets in neurodegeneration, cancer and parasitic infections.Open biology · 2025Review
- Occipital hypoperfusion and motor reserve in Parkinson's disease: an early-phaseNPJ Parkinson's disease · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The development of therapeutic interventions for Parkinson disease (PD) is challenged by disease complexity and subjectivity of symptom evaluation. A Parkinson's Disease Related Pattern (PDRP) of glucose metabolism via fluorodeoxyglucose positron emission tomography (FDG-PET) has been reported to correlate with motor symptom scores and may aid the detection of disease-modifying therapeutic effects. Objectives: We sought to independently evaluate the potential utility of the PDRP as a biomarker for clinical trials of early-stage PD. Methods: Two machine learning approaches (Scaled Subprofile Model (SSM) and NPAIRS with Canonical Variates Analysis) were performed on FDG-PET scans from 17 healthy controls (HC) and 23 PD patients. The approaches were compared regarding discrimination of HC from PD and relationship to motor symptoms. Results: Both classifiers discriminated HC from PD (p < 0.01, p < 0.03), and classifier scores for age- and gender- matched HC and PD correlated with Hoehn & Yahr stage (R Conclusions: Two independent analyses performed in a cohort of mild PD patients replicated key features of the PDRP, confirming that FDG-PET and multivariate classification can provide an objective, sensitive biomarker of disease stage with the potential to detect treatment effects on PD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.